Principal Researcher		Haruo S	ugiyama				Number of		4	
							Reser	chers		
Research Institution		Professor and Chairman,				Location of Suita, Osaka				
· Department · Title		Department of Clinical Laboratory Science,				Insti	tution			
		Osaka University Medical School								
Title of	Development of immunotherapy against leukemia targeting WT1 protein									
Project										
Abstract of	Wilms' tumor gene product (WT1 protein) is overexpressed in almost all of leukemias									
Research	and a new tumor rejection antigen. Therefore, we planned to develop leukemia									
Project	ject immunotherapy targeting WT1 protein. After optimization of WT1 vaccine by using murine models, we started clinical trials of WT1 peptide-based immunotherapy for patients with leukemias. In the very near future, we will be able to optimise WT1 vaccine for treatment of leukemia.									
References	Sugiyama, H. Cancer immunotherapy targeting WT1 protein. International Journal of Hematology, 76: 127-132, 2002.									
Term of Project	Fiscal years 2003-2007. (5years)									
Budget	FY200	03	FY2004	FY200	05	FY200	5	FY2007	TOTAL	
Allocation	2	8,500	27,000	1	8,000	9	,000,	9,000	91,500	
(in thousand of yen)										
Homepage Address				http://sal	http://sahswww.med.osaka-u.ac.jp/~hmtonc/index.html					